Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are tuned to interfere with the division process of cancer cells [Science of TTFields]. TTFields are delivered to the region of the cancer using an investigational medical device, called the NovoTTF-100M System. The system is a portable, light-weighted, battery operated device designed to deliver TTFields to brain metastasis from non-small cell lung cancer. Patients receiving TTFields need to wear four transducer arrays on their scalp, which deliver the fields non-invasively to the brain. The system is intended for continuous home use by patients [Living with TTFields].

TTFields have been approved by the FDA for treatment of adult patients suffering from recurrent and newly diagnosed glioblastoma. Nevertheless, this investigational system is not FDA approved to treat brain metastases from non-small cell lung cancer. Therefore, the safety and efficacy of TTFields in this condition is still unknown, and will be evaluated in this clinical trial [The METIS Trial].